News | August 03, 2022
Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
he US FDA has issued six observations pursuant to the completion of the audit.
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
